Inappropriate use of prescribed psychotropic drugs: Intravenous diazepam in the psychiatric emergency.
DOI:
https://doi.org/10.20453/rnp.v84i2.4001Keywords:
Diazepam, benzodiazepines, substance-related disordersAbstract
Benzodiazepines (BZDs) are essential drugs used in the treatment of different health problems: Peru’s National Drug Petitionary lists five of them allowed for oral or parenteral administration. At the beginning in the 1960s, BZDs were widely and unrestrictedly prescribed; the subsequent development of tolerance and withdrawal phenomena, triggered by their prolonged use, led to drastic prescription restrictions, sometimes below the real clinical needs. Although BZDs are included in the Drug Enforcement Administration (DEA) group IV of controlled substances, it is accepted that, in general, they are not primary drugs of abuse, and the development of addictive phenomena only occurs in the presence of comorbidity with other drug addictions. It is necessary to distinguish between the "inappropriate use" or "misuse" of the BZDs and those cases that meet criteria of full dependence. There are few reported cases of inappropriate use of BZD prescribed by parenteral route. The case reported here is one of a 51-years-old woman who, over the course of several years, went to a psychiatric emergency service due to crisis of dysphoria and anxiety (but not a panic attack), and received on several occasions, intravenous injections of diazepam, to the point that later she used to go repeatedly to demand such medication, without being medically necessary. It is, therefore, important for the prescribing professional to use parenteral BZDs cautiously and carefully, in order to prevent an addictive process that can generate serious consequences.
References
World Health Organization. Programme on substance abuse. Rational use of benzodiazepines. Copenhagen: WHO; 1996.
Instituto Nacional de Salud Mental. Estudio Epidemiológico de Salud Mental en Lima Metropolitana y Callao. Replicación 2012. Informe General. Anales de Salud Mental. 2013; 29(Sup1): 0-0.
Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: A systematic review. Drug Alcohol Depend. 2019; 200: 95–114.
Dell’osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry. 2013; 28:7-20.
Blanco C, Han B, Jones CM, Johnson K, Compton WM. Prevalence and correlates of benzodiazepine use, misuse, and use disorders among adults in the United States. J Clin Psychiatry. 2018; 79 (6): 12174. doi: 10.4088/JCP.18m12174
Ortiz-Lobo A, Sobrado AM. El malestar que producen los problemas de la vida. AMF. 2013; 9:366-372.
Borràs-Vives R, Boada-Loro S, Casamitjana- Cucurella N, Casas-Sánchez X, Guayta-Escolies R, Gironella-Ferrer C, et al. Abuso de medicamentos: ¿la adicción del siglo XXI? FMC. 2007; 14:255-262.
Weaver M. Prescription sedative misuse and abuse. Yale J Biol Med. 2015; 88:247-256.
Isaacson JH, Hopper JA, Alford DP, Parran T. Prescription drug use and abuse. Postgrad Med. 2005; 118: 19-26.
National Institute on Drug Abuse; National Institutes of Health; U.S. Department of Health and Human Services. El uso indebido de los medicamentos recetados - Reporte de investigación. Washington DC: National Institute on Drug Abuse; 2020. Disponible en: https://www.drugabuse.gov/es/ publicaciones/los-medicamentos-de-prescripcion- abuso-y-adiccion/panorama-general 08/08/2020
Parran T. Prescription drug abuse. Med Clin North Am. 1997; 81: 967-978.
Nielsen S. Benzodiazepines. En: Nielsen S, Bruno R, Schenk S (eds.). Non-medical and illicit use of psychoactive drugs. Cham: Springer; 2017. pp. 141- 160.
Kaminer Y, Modai I. Parenteral abuse of diazepam: a case report. Drug Alcohol Depend. 1984; 14(1):63- 65.
Liebrenz M, Schneider M, Buadze A, Gehring MT, Dube A, Caflisch C. High-dose benzodiazepine dependence: A qualitative study of patients’ perceptions on initiation, reasons for use, and obtainment. Plos One. 2015; 10(11): e0142057.
Weaver M. Prescribing medications that have potential for abuse. J Clin Outcomes Manag. 2009; 16: 171-179.
Schmitz A. Benzodiazepine use, misuse, and abuse: A review. Ment Health Clin. 2016; 6: 120-126.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Arlington, VA: American Psychiatric Association; 2013.
Stahl SM. Prescriber’s guide. 6th ed. London: Cambridge University Press; 2017.
Shaner R. Benzodiazepines in psychiatric emergency settings. Psychiatr Ann. 2000; 30: 268-275.
Singh RKL, Jain R, Ray R, Gupta YK. Abuse liability of diazepam through different routes. Indian J Physiol Pharmacol. 2001; 45:181-190.
Garriga M, Pacchiarotti O, Kasper S, Zeller SL, Allen MH, Vazquez G, et al. Assessment and management of agitation in psychiatry: expert consensus. World J Biol Psychiatry. 2016;17:86–128. doi: 10.3109/15622975.2015.1132007
Vieta E, Garriga M, Cardete L, et al. Protocol for the management of psychiatric patients with psychomotor agitation. BMC Psychiatry. 2017; 17:328. doi: 10.1186/s12888-017-1490-0
Starcevic V. The reappraisal of benzodiazepines in the treatment of anxiety and related disorders. Expert Rev Neurother. 2014; 14: 1275–1286. doi: 10.1586/14737175.2014.963057
de las Cuevas C, Sanz E, de la Fuente J. Benzodiazepines: more “behavioural” addiction than dependence. Psychopharmacology. 2003; 167: 297– 303. doi: 10.1007/s00213-002-1376-8
Balon R, Starcevic V, Silberman E, Cosci F, Dubovsky S, Fava GA, et al. The rise and fall and rise of benzodiazepines: a return of the stigmatized and repressed. Braz J Psychiatry. 2020; 42: 243-244. doi: 10.1590/1516-4446-2019-0773